Modeling and Simulation Archives

Guide

How to Leverage PBPK Modeling and Simulation in Drug Research and Development

Learn how PBPK modeling and simulation in drug research and development reduces clinical burden, supports…

CertaraMay 12, 2026

Poster

Predicting FcRn-Mediated PK/PD with PBPK Modeling

Learn how PBPK modeling predicts FcRn binder PK/PD and IgG dynamics across species.

CertaraMay 12, 2026

Poster

Predicting Ocular Drug Behavior with PBPK Modeling

Learn how PBPK modeling predicts ocular drug exposure and target occupancy to optimize anti-VEGF therapies…

CertaraMay 12, 2026

Poster

Advancing In Vivo CAR-T with QSP

Learn how QSP modeling improves first-in-human dose selection for CAR-T therapies, enabling better translation and…

CertaraMay 12, 2026

Video

Certara IQ™ Demo

Watch a short demo of Certara IQ™, a QSP platform for modeling, simulation, and analysis.…

CertaraMay 12, 2026

Webinar

Minimize risk when preparing for hepatic impairment studies

CertaraMay 12, 2026

Webinar

Expert Q&A: Identify Winning Biotherapeutics in Early Discovery

CertaraMay 11, 2026

Webinar

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

CertaraMay 8, 2026

Guide

Designing Drug Development Programs for Reimbursement Success

Download the guide to learn how model-informed drug development, QSP, and MBMA help align with…

CertaraMay 7, 2026

Publication

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…

CertaraMay 7, 2026

Modeling and Simulation

How to Leverage PBPK Modeling and Simulation in Drug Research and Development

Predicting FcRn-Mediated PK/PD with PBPK Modeling

Predicting Ocular Drug Behavior with PBPK Modeling

Advancing In Vivo CAR-T with QSP

Certara IQ™ Demo

Minimize risk when preparing for hepatic impairment studies

Expert Q&A: Identify Winning Biotherapeutics in Early Discovery

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

Designing Drug Development Programs for Reimbursement Success

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

Newsletter sign up

Quick links

Solutions

Contact